Media headlines about Sorrento Therapeutics (NASDAQ:SRNE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sorrento Therapeutics earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.7243538517903 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of NASDAQ:SRNE opened at $6.30 on Friday. The company has a current ratio of 0.38, a quick ratio of 0.38 and a debt-to-equity ratio of 0.03. Sorrento Therapeutics has a 12-month low of $1.50 and a 12-month high of $10.65. The stock has a market capitalization of $555.27, a price-to-earnings ratio of -5.53 and a beta of 2.43.

SRNE has been the topic of a number of analyst reports. ValuEngine raised Sorrento Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub raised Sorrento Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 6th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective (up previously from $20.00) on shares of Sorrento Therapeutics in a research note on Tuesday, January 16th. Finally, Oppenheimer reaffirmed a “buy” rating and set a $9.00 price objective on shares of Sorrento Therapeutics in a research note on Friday, January 19th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Sorrento Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $15.33.

In other Sorrento Therapeutics news, major shareholder Abg Management Ltd sold 70,721 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $8.00, for a total value of $565,768.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider George K. Ng purchased 90,000 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was acquired at an average cost of $9.95 per share, for a total transaction of $895,500.00. Following the completion of the purchase, the insider now owns 1,906,177 shares in the company, valued at approximately $18,966,461.15. The disclosure for this purchase can be found here. Over the last three months, insiders sold 530,721 shares of company stock worth $4,012,668. 5.00% of the stock is owned by corporate insiders.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc, a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases.

Insider Buying and Selling by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.